Daré Bioscience, Inc. (NASDAQ: DARE), a health biotech firm committed to enhancing women”s health, has announced a new contract with the Gates Foundation. This agreement allows Daré to potentially receive funding of up to approximately $300,000 to conduct an assessment of the global landscape regarding organizations involved in contraceptive product development.
The objective of this project is to identify and evaluate both for-profit and non-profit entities worldwide that possess expertise in various areas critical to contraceptive innovation, including formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support.
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, expressed her gratitude for the support from the Gates Foundation, stating, “We are honored to be selected to receive funding from the Gates Foundation to help strengthen the global contraceptive innovation ecosystem. Daré”s mission is to close critical gaps in care using rigorous science and technologies that serve her needs. This initiative will help identify potential strategic partners for the foundation that can help to accelerate the translation of new contraceptive concepts into products that make a meaningful difference globally.”
Johnson further noted that this initiative builds upon Daré”s established expertise in developing women”s health products and its history of collaboration with both public and private sector partners to promote innovative solutions in contraceptive and reproductive health.
Daré Bioscience focuses exclusively on addressing the gaps in women”s health through scientifically grounded innovations. The company is dedicated to advancing products that meet rigorous clinical standards, including randomized controlled trials and compliance with current Good Manufacturing Practice (cGMP) guidelines.
Despite advances in women”s health discussions, especially concerning menopause and sexual health, access to effective, evidence-based solutions remains limited. Daré aims to change this narrative by providing credible, science-driven therapies.
For additional information about Daré”s mission and its pipeline of innovations, interested parties can visit www.darebioscience.com.
Daré”s leadership has been recognized in notable lists such as Medicine Maker”s Power List and Endpoints News” Women in Biopharma, with Johnson being highlighted among Fierce Pharma”s Most Influential People in Biopharma for her contributions to women”s health innovation and advocacy.
The company may share material information regarding its operations, products, and financial status through various channels, including its Investors section on its website, SEC filings, press releases, and social media. Investors and media representatives are encouraged to monitor these communications for relevant updates.
In regard to forward-looking statements, Daré cautions that all comments beyond historical facts are speculative. Various risks and uncertainties could affect Daré”s actual results, which may differ from those anticipated in forward-looking statements. These include, but are not limited to, challenges in fulfilling the contract with the Gates Foundation, reliance on third-party collaborators, and the ability to secure additional funding.
For further inquiries, please contact Daré Bioscience Investor Relations at [email protected].
